Effectiveness of N-Acetylcysteine (NAC) in Treating Cocaine Dependent Individuals - 1



Status:Completed
Conditions:Psychiatric, Pulmonary
Therapuetic Areas:Psychiatry / Psychology, Pulmonary / Respiratory Diseases
Healthy:No
Age Range:18 - 65
Updated:1/17/2019
Start Date:November 2005
End Date:May 2010

Use our guide to learn which trials are right for you!

A Controlled Trial of N-Acetylcysteine (NAC) for Cocaine Dependence

Currently, no effective drug treatment exists for cocaine dependence. Glutamate levels are
disrupted with long-term cocaine use. N-acetyl cysteine (NAC) is a drug that is metabolized
by the body to form cysteine, an active compound that normalizes glutamate levels. The
purpose of this study is to determine the safety and effectiveness of NAC in treating cocaine
dependent individuals.

Currently, no effective pharmacological treatment exists for cocaine dependence. Long-term
use of cocaine disrupts normal glutamate levels. If addicts stop using cocaine, glutamate
levels drop, which encourages addicts to continue seeking the drug. NAC is a drug that
increases intracellular cysteine levels, which in turn leads to normalization of glutamate
levels. Currently, NAC is used for the treatment of cystic fibrosis, heart disease, and
acetaminophen overdose. Since NAC has the capability of restoring normal glutamate levels, it
holds potential as a treatment for cocaine dependence. The purpose of this study is to
determine the safety and effectiveness of NAC in treating cocaine dependent individuals. In
addition, this study will evaluate cocaine craving and withdrawal symptoms in individuals
taking NAC.

Participants in this double-blind, placebo-controlled trial will be randomly assigned to
receive either NAC or placebo. All participants will undergo an initial evaluation, which
will include a physical examination, an electrocardiogram, blood samples, urine tests, and
cue reactivity measures. Participants in the NAC group will receive either 600 mg or 1200 mg
of NAC, two times each day for 8 weeks. In addition, all participants will receive cognitive
behavioral therapy throughout the study on a weekly basis. Cocaine use will be confirmed by a
urine drug screen test, three times each week. Participants will be assessed on a number of
biomedical and psychosocial variables known to influence cocaine treatment outcomes. After
Week 2, participants will repeat the cue reactivity procedures, which will include measuring
a participant's craving response when exposed to conditioned reminders of prior cocaine use.

Inclusion Criteria:

- Meets DSM-IV criteria for cocaine dependence, as determined by a mini-SCID interview

- Currently dependent on cocaine

- Seeking treatment for cocaine abuse at the time of study entry

- Currently uses cocaine by smoking, nasal, or intravenous route of administration.

- Stable physical and mental health, as judged by an interview and physical examination

- If female, demonstrates a negative pregnancy test and agrees to use an adequate method
of contraception for the duration of the study

- Lives within a 50 mile radius of the research program center and has reliable
transportation

Exclusion Criteria:

- Meets DSM-IV criteria for dependence on any psychoactive substance other than cocaine,
alcohol, nicotine, or marijuana

- Physiological dependence on alcohol, which requires medical detoxification

- History of significant liver, kidney, endocrine, cardiac (e.g., arrhythmia requiring
medication, angina pectoris, myocardial infarction), stroke, seizure, neurological,
non-drug-related psychiatric, gastrointestinal, pulmonary, hematologic, or metabolic
disorders (e.g., homocystinuria)

- History of an adverse reaction to cocaine, including loss of consciousness, chest
pain, psychosis, or seizure

- History of adverse reaction or hypersensitivity to N-acetyl cystine (NAC), or a
similar drug

- Significant active medical or psychiatric illness that might inhibit the ability to
complete the study

- Active high blood pressure, defined as a mean of three sitting blood pressure readings
of 145/95 or higher within a 10-day period

- History of or current asthma

- Occasional or daily use of albuterol or other beta-agonist inhalers

- Use of carbamazepine, phenytoin, nitrous oxide, methotrexate, 6 azauridine triacetate,
or nitroglycerin within the 2 weeks prior to study entry

- Use of very large doses of folate, cyanocobalamine (vitamin B12), or pyridoxine
(vitamin B6) as prescribed by a health care professional; individuals taking very
large doses of these vitamins on a self-initiated basis may enter the study if they
are willing to stop use 14 days prior to study entry and to use a standard generic
multiple vitamin instead

- Pregnant or breastfeeding

- Required by the court to obtain treatment for cocaine dependence

- Not seeking treatment for cocaine dependence

- Anticipating elective surgery or hospitalization within 20 weeks of study entry

- Failure to have a consistent residence for the 4 weeks prior to study entry

- History of childhood or adult seizures

- Participated in cocaine treatment (clinical or research) within 30 days of study entry
We found this trial at
1
site
171 Ashley Avenue
Charleston, South Carolina 29425
843-792-1414
Medical University of South Carolina The Medical University of South Carolina (MUSC) has grown from...
?
mi
from
Charleston, SC
Click here to add this to my saved trials